

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number 10/134,187  
 Filing Date 04/26/2002  
 First Named Inventor KREAM, RICHARD M.  
 Art Unit 1614 1647  
 Examiner Name Landsman  
 Attorney Docket Number


Sheet of

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
RL		US 5,891,842(B1)	04/06/99	Kream, Richard	
RL		US 6,310,072 (B1)	10/30/01	Smith, Marge, et al	
RL		US 6,063,758(B1)	05/16/00	Lappi, Douglas, et al	
		US 09/428,692	Unpub.	Carr, Daniel, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
RL		PCT WO 01/30371 (A@)	05/03/01	Carr, Daniel, et al.		
		11060598	08/15/97	Matsumura		

Examiner  
Signature

Date  
Considered

12/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Compleat if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/720,039
		Filing Date	
		First Named Inventor	
		Group Art Unit	1647
		Examiner Name	Landsman
		Attorney Docket Number	
Sheet		of	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
BK		REULER, et al., <i>The Chronic Pain Syndrome: Misconceptions &amp; Management</i> , ANN INTERN MED. 93:588-596 (1980)	
		SRIWATANKUL, et al, <i>Analysis of Narcotic Analgesic usage in the Treatment of Postoperative Pain</i> , JAMA 250:926-929 (1983)	
		SCHECHTER, <i>Pain &amp; Pain Control in Children</i> , CURRENT PROBLEMS IN PEDIATRICS 15 (1985)	
		GOODMAN & GILMAN, <i>The Pharmacological Basis of Therapeutics</i> 511 (7 <sup>th</sup> ed. 1985)	
		FORAN, et al, <i>A Substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic</i> , 97 PNAS 13:7521-26 (2001)	
		EGELTON, et al, <i>Transport of Opioid Peptides into the Central Nervous System</i> , J PHARM SCI 1998, 87(11):1433-39	
		BORCHARD, <i>Optimizing oral absorption of peptides using prodrug strategies</i> , J CONTROL RELEASE 1999; 62(1-2):231-38	
		STAIN-TEXIER, <i>Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability</i> , BR J PHARMACOL 1999; 128(4):917-24	
		MERRIFIELD, <i>Solid Phase Synthesis</i> , SCIENCE 232: 241-47 (1986)	
		BARANY, et al, <i>Solid-phase peptide synthesis; a silver anniversary report</i> , INT'L J PEPTIDE PROTEIN RES 30:705-39 (1987)	
		KENT, <i>Chemical Synthesis of Peptides and Proteins</i> , ANN REV BIOCHEM 57:857-989 (1988)	

Examiner Signature	<i>[Signature]</i>	Date Considered	12.1.05
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/134,187
		Filing Date	04/26/2002
		First Named Inventor	KREAM, RICHARD M.
		Group Art Unit	1614 / 1647
		Examiner Name	
Sheet	of	Attorney Docket Number	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
Bc		KAISER, et al, <i>Peptide &amp; Protein Synthesis by Segment Synthesis-Condensation</i> , SCIENCE 243:187-98 (1989)	
		KREAM, <i>Substance P markedly potentiates the antinociceptive effects of morphine sulphate administered at the spinal level</i> , 90 PNAS 5564-68 (1993)	
		MASCZYNSKA, et al, <i>Alternative forms of interaction of substance P and opioids innocicpetive transmission</i> , LTRS PEPTIDE SCI 298, 5:395-98 (1998)	
		MASCZYNSKA, et al, <i>Dual Functional Interactions of Substance P Opioids in Nociceptive Transmission</i> , ANALGESIA 3:259-68 (1998)	
		WATSON, et al, <i>Tissue Selectivity of Substance P Alkyl Esters Suggesting Multiple Receptors</i> , EURO J PHARMACOL 87:77-84 (1983)	
		SIZHENG, et al, <i>Opioid and neurokinin activities of substance P fragments and their analogs</i> , EURO J PHARMACOL 193:209-15 (1991)	
		LIPKOWSKI, et al, <i>An Approach to the Self Regulatory Mechanism of Substance P Actions</i> , 33 LIFE SCIENCES 141-44 (1983)	
		FORAN, et al, <i>Inhibition of Morphine tolerance Development by a Substance P-Opioid Peptide Chimera</i> , J PHARMACOL & EX THERA 295:3:1142-48 (2000)	
		LIPKOWSKI, et al, <i>Opioid Peptide Analogues: Reconsideration as a Potentially New Generation of Analgesics</i> , POLISH J CHEM, 68:907-12 (1994)	
		MISTEREK, et al, <i>Spinal Co-Administration of Peptide Subsnace P Antagonist Increases Antinociceptive Effect of the Opioid Peptide Biphalin</i> , 14 LIFE SCIENCES, 14:939-44 (1994)	
V		FORAN, et al, <i>Chimeric Peptide for the Treatment of Acute &amp; Chronic Pain</i> , ANESTHESIOLOGY 91:3A:A944 (1999)	

Examiner Signature <i>[Signature]</i>	Date Considered 12.1.05
---------------------------------------	-------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

(use as many sheets as necessary)

Sheet		of
-------	--	----

**Complete if Known**

Application Number	10/134,187
Filing Date	04/26/2002
First Named Inventor	KREAM, RICHARD M.
Group Art Unit	<del>1614</del> 1647
Examiner Name	
Attorney Docket Number	

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

[illegible]

**Examiner  
Signature**

Date Considered	12.1.05
-----------------	---------

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/134, 187		
		Filing Date	04/26/2002		
		First Named Inventor	KREAM, RICHARD M.		
		Art Unit	<del>4614</del> 1647		
		Examiner Name			
Sheet	1	of	1	Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
pk		LIPKOWSKI, ET AL, Neuropeptides: Peptide and Nonpeptide Analogs, PEPTIDES: SYNTHESIS, STRUCTURES AND APPLICATIONS. 1995, PP 287-320. ACADEMIC PRESS.	

Examiner Signature		Date Considered	12.1.05
-----------------------	-------------------------------------------------------------------------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.